Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer

Thongprasert S, Permsuwan U, Ruengorn C, Charoentum C, Chewaskulyong B

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22151987

DOI
10.1111/j.1743-7563.2011.01463.x

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carboplatin /administration & dosage; Carcinoma, Non-Small-Cell Lung /drug therapy /economics /pathology; Cisplatin /administration & dosage; Cost-Benefit Analysis; Etoposide /administration & dosage; Female; Humans; Lung Neoplasms /drug therapy /economics /pathology; Male; Middle Aged; Neoplasm Staging; Paclitaxel /administration & dosage

AccessionNumber
2201200097

Date bibliographic record published
15/02/2012